European marketing authorization for Trimbow as asthma treatment

The European Commission has granted marketing authorization for Trimbow (beclomethasone/formoterol/glycopyrronium), an extrafine formulation triple fixed combination therapy in a single inhaler, as a maintenance treatment for adult asthma patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and medium dose of inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous year.

The application was filed by Italian family-owned drugmaker Chiesi Group, and the Commission’s approval follows a November 2020 positive recommendation by the European Medicines Agency’s advisory committee.